Hyderabad, March 31: Suven Life Sciences Ltd has secured product patents in Mexico and Korea for two of its new chemical entities (NCEs).
These NCEs are developed for the treatment of disorders associated with neurodegenerative diseases.
“We are very pleased by the issue of these patents to Suven for our drug candidates that are being developed for central nervous system disorders which targets an $18 billion potential market opportunity globally,” Mr Venkat Jasti, CEO of Suven, said in a release.
The patents, valid until 2023, were the exclusive intellectual property of Suven and had been achieved through the exclusive internal discovery research efforts. Products out of these inventories, which were in pre-clinical development, may be out-licensed at the clinical phase-I or phase-II stage, he added.
The granted claims of the patents included the class of selective 5-HT compounds discovered by the Hyderabad-based company, which were being developed as therapeutic agents to be useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer’s, Parkinson, Schizophrenia and Huntington’s, the release said.